Surgical technique Shapes and Sizes*

Free Hand Mini Arthro Kit

01600401 2,0 x 3,0 x 0,2 cm
01600400 3,0 x 4,0 x 0,2 cm
01600403 Ø = 1,2 cm H = 0,2 cm
01600405 Ø = 1,5 cm H = 0,2 cm
01600404 Ø = 1,8 cm H = 0,2 cm
Chondro+ Slim Prime
MaioRegen Chondro+

01600289 2,0 x 3,0 x 0,4 cm

01600287 3,0 x 4,0 x 0,4 cm
01600290 Ø = 1,2 cm H = 0,4 cm
01600282 Ø = 1,5 cm H = 0,4 cm
01600292 Ø = 1,8 cm H = 0,4 cm

MaioRegen Slim

01600288 2,0 x 3,0 x 0,6 cm

01600286 3,0 x 4,0 x 0,6 cm
01600285 Ø = 1,2 cm H = 0,6 cm
01600275 Ø = 1,5 cm H = 0,6 cm
01600291 Ø = 1,8 cm H = 0,6 cm

MaioRegen Prime
* All products cleared for CE marketing (regulation EU 745/2017)
Not yet FDA approved

A SYSTEM
TAILORED TO YOUR PATIENTS’ NEEDS

Guarda il video
MDU 006003-02-00
Fin-Ceramica Faenza Spa
via Granarolo 177/3 - 48018 Faenza RA, Italy
t +39 0546 645411 - f +39 0546 46763
info@finceramica.it - www.finceramica.it
 is a joint surface restoration system for the treatment
of cartilage and osteochondral lesions, with a comprehensive range of
solutions for all the pre-osteoarthritis stages, and supported by the highest
level of scientific evidence.
Available in three different configurations, each for a specific indication,
PILOT CLINICAL STUDY Results from a Level of Evidence I international RCT*
•Kon E. et al., AJSM, 2011 - 28 Patients - 2 years follow-up The study has been conducted to assess the benefit provided by MaioRegen Prime (tri-layer) scaffold.
•Kon E. et al., AJSM, 2013 - 27 Patients - 5 years follow-up
•Di Martino et al., AJSM 2021 - 24 Patients - 10 years follow-up IKDC SUBJ. SCORE
2 YEARS FUP

MaioRegen is a biomimetic resorbable device ready to use and easily Demographic and lesions data 90

p < 0.0001
implantable through a straight-forward surgical approach. • 28 Patients: 19 ♂ - 9 ♀
• Mean age (years ± SD): 35.3±10.2
LESIONS SITES 67.5
Statistical significant improvement in IKDC
• Average lesions size: 2.9 ± 1.3 cm2 Subjective Score for patients treated with
LFC; 5
• Lesions aetiology: o 6 OCD MaioRegen from baseline to 2 years follow-up.
45
o 17 Microtraumatic/degenerative Patella; 12
o 5 Traumatic 66.7

Chondro+ Chondral lesions, with mild or no impairment 1+ Complex cases

PREVIOUS SURGERIES ASSOCIATED SURGERIES
22.5
43.2
of subchondral bone tissue. MFC; 8
(20 PTS) (15 PTS) 0
BASELINE 24 mths
11 cartilage surgery 7 lateral release/patellar n = 51
7 meniscal surger realigment
4 ACL reconstruction 4 osteotomy
3 lateral release/patellar 2 meniscal surgery Tibial...

2 realigment 1 ACL reconstruction Trochlea; 7

Slim Deep chondral and osteo-chondral lesions,

7 other 3 other Evidence of MaioRegen superiority vs microfracture
with moderate bone impairment.
Clinical evaluation
100

IKDC SUBJECTIVE TEGNER p = 0.036 Deep Osteochondral Lesions

80

IKDC SUBJ. SCORE

100 10
90 9
Statistically significant MaioRegen superiority:

2 YEARS FUP
80 8 60
+12.4 points vs Microfracture in change from

3
70 7 77.7
40 baseline of IKDC Subjective score.
Prime Osteo-chondral lesions with severe bone
60
50
6
5
64.3
impairment. 40 4
20
30 3
20 2
0
40.5 77,0 78,6 78,0 MAIOREGEN MICROFRACTURES
10 1 n = 27 n = 30
0 0

Clear clinical indications based on the specific disease stage BASAL

P < 0,005
24 M 60 M 120 M PRE-INJ PRE-OP
P < 0,005
24 M 60 M 120 M
100

Sport Active Patients

P < 0,005 P < 0,005 p = 0.027
80

IKDC SUBJ. SCORE

2 YEARS FUP
60 Statistically significant MaioRegen superiority:
From Results: 76.2 +16.0 points vs Microfracture in change from
40 64.2 baseline of IKDC Subjective score.
“The analysis of this population showed a statistically significant improvement of all
clinical scores from the baseline to the final evaluation” 20

0
MAIOREGEN MICROFRACTURES
From Discussion: n = 16 n = 11

“The main finding of this study is that this cell-free biomimetic osteochondral 100

scaffold provided a significant clinical improvement in patients affected by

p = 0.144 Osteochondritis Dissecans
80

IKDC SUBJ. SCORE

symptomatic knee lesions, which was stable over time” Clinically relevant improvement of MaioRegen:

2 YEARS FUP
60
“A significant improvement of the clinical scores was observed at long-term follow- +12.0 points vs Microfracture in change from
76.7 baseline of IKDC Subjective score.
40
up after surgery, regardless of the number of previous or concurrent surgical 61.9
20
procedures. Considering the variety of characteristics of this heterogeneous
1+ 2 3 group of patients, this series can closely represent the real clinical setting of 0
MAIOREGEN
n = 15
MICROFRACTURES
n = 12
middleaged patients presenting with articular surface lesions who can obtain an
Cartilage defects Osteo-chondral defects Advanced OA overall benefit from this technique.” Clear Clinical Indications: RCT analysis in above sub-populations confirms the superiority of MaioRegen compared to microfracture.

* Kon et al., KSSTA, 2017